Direct oral anticoagulants in cirrhosis: Rationale and current evidence
Cindy Pereira Portela, Lucas A. Gautier, Maxime G. Zermatten, Montserrat Fraga, Darius Moradpour, Debora Bertaggia Calderara, Alessandro Aliotta, Lucas Veuthey, Andrea De Gottardi, Guido Stirnimann, Lorenzo Alberio
Abstract
pharmacokinetic and pharmacodynamic studies), as well as clinical outcomes in patients with cirrhosis on DOAC.
Topics & Concepts
MedicineIntensive care medicineDabigatranAtrial fibrillationCirrhosisDirect thrombin inhibitorStroke (engine)Liver diseasePopulationDiscovery and development of direct thrombin inhibitorsInternal medicineWarfarinThrombinPlateletMechanical engineeringEngineeringEnvironmental healthLiver Disease and TransplantationLiver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection